medigraphic.com
Academia Mexicana de Neurología, A.C.

2017, Number 3

Next >>

Rev Mex Neuroci 2017; 18 (3)

Sub-chronic administration of St. John’s wort reverses anxiety- and depressive-like behaviors induced by two different protocols of chronic stress

Rojas-Carvajal M, Fornaguera J, Badilla S, Brenes JC, Calvo MF

Language: English
References: 24
Page: 2-10
PDF size: 163.17 Kb.


ABSTRACT

Introduction. St. John’s wort (Hypericum perforatum, HP) is one of the most used herbal medicines. Here we investigated the putative antidepressive- and anxiolytic-like effects of HP, by using a wellvalidated rat model of anxiety and depression based on chronic stress.
Methods. To this purpose, subjects were either immobilized (INM) or randomly exposed to different stressors (chronic unpredictable stress: CUS) during 30 days. Forty-eight hours after the last stress session, subjects of each stress condition were randomly assigned to the HP (100 mg/kg), diazepam (5 mg/kg) or saline groups. Immediately after a baseline measure and during 10 consecutive days, drugs were intragastrically administrated. During this period, four open-field and elevated plus-maze tests were carried out every other day.
Results. CUS and INM stress were found to induce an anxiety- and depressive-like phenotype in both tests, whereas HP and diazepam progressively restored this stress-dependent phenotype. HP potency was almost equivalent to that of the diazepam. However, diazepam peaked slightly sooner and remained unaltered throughout the testing days, whereas HP peaked gradually and required more administrations to reach diazepam levels.
Conclusion. HP seems to be a promising alternative treatment for anxiety and mood disorders that may have wider safe-dosing ranges and fewer side-effects than benzodiazepines.


REFERENCES

  1. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychological Med 2013; 43: 897–910.

  2. Facts and Statistics. Anxiety and Depression Association of America, 2015. Accessed July 27, at http://www.adaa.org/about-adaa/press-room/facts-statistics.

  3. Zamorski MA, Albucher RC. What to do when SSRIs fail: Eight strategies for optimizing treatment of panic disorder. American Family Physician 2002; 66: 1477–1484.

  4. Zhang X. General guidelines for methodologies on research and evaluation of traditional medicine. World Health Organization 2000, 1–71.

  5. Butterweck V and Schmidt M. St. John’s wort: role of active compounds for its mechanism of action and efficacy. Wien Klin Wochenschr 2007; 157: 356–361.

  6. Cooper, M. Anxiety Disorders: A Developmental Vulnerability-Stress Perspective. In: Hankin BL, Abela JR, eds. Development of psychopathology: A vulnerability-stress perspective. California: Sage Publications, 2005: 289-327.

  7. Zafar HM, Paré WP, Tejani-Butt SM. Effect of acute or repeated stress on behavior and brain norepinephrine system in Wistar-Kyoto (WKY) rats. Brain Research Bull 1997; 44: 289–295.

  8. Katz RJ, Roth KA, Carroll BJ. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci & Biobehav Rev 1981, 247–251.

  9. Blanchard DC, Griebel G, Pobbe R, Blanchard RJ. Risk assessment as an evolved threat detection and analysis process. Neuroscience & Biobehav Rev 2011; 35: 991–998.

  10. Ennaceur A. Tests of unconditioned anxiety—Pitfalls and disappointments. Phys & Behav 2014; 135: 55–71.

  11. Gorka Z, Moryl E, Papp M. Effect of chronic mild stress on circadian rhythms in the locomotor activity in rats. Pharma Biochem & Behav 1996; 54: 229–234.

  12. Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H. Chronic restraint stress causes anxiety-and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Progress in Neuro-Psychopharm and Bio Psychiatry 2012; 39: 112–119.

  13. Bondi CO, Rodriguez G, Gould GG, Frazer A, Morilak DA. Chronic unpredictable stress induces a cognitive deficit and anxiety-like behavior in rats that is prevented by chronic antidepressant drug treatment. Neuropsychopharma 2008; 33: 320–331.

  14. Zhao Y, Wang Z, Dai J, Chen L, Huang Y, Zhan Z. Beneficial effects of benzodiazepine diazepam on chronic stress-induced impairment of hippocampal structural plasticity and depression-like behavior in mice. Behav Brain Research 2012; 228: 339–350.

  15. Hegarty AA, Vogel WH. The effect of acute and chronic diazepam treatment on stress-induced changes in cortical dopamine in the rat. Pharma Biochem & Behav 1995; 52: 771–778.

  16. Padovan, C. M., Guimaraes, F. S. Restraint-induced hypoactivity in an elevated plus-maze. Brazilian J Med and Bio Research 2000; 33: 79–83.

  17. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A. Diminished anxiety-and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neuroscience 2002; 22: 10046–10052.

  18. Trofimiuk E, Walesiuk A, Braszko JJ. St John’s wort (Hypericum perforatum) diminishes cognitive impairment caused by the chronic restraint stress in rats. Pharma Research 2005; 51: 239–246.

  19. Vandenbogaerde A, Zanoli P, Puia G, Truzzi C, Kamuhabwa A, De Witte P, Merlevede W, Baraldi M. Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats. Pharma Biochem & Behav 2000; 65: 627–633.

  20. Kumar A, Garg R, Prakash AK. Effect of St. John’s Wort (Hypericum perforatum) treatment on restraint stress-induced behavioral and biochemical alteration in mice. BMC Complementary and Alternative Med 2010; 10 (18).

  21. Hypericum Depression Trial Study Group (HDTSG). Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. Jama 2002; 287: 1807–1814.

  22. Kasper S, Caraci F, Forti B, Drago F, Aguglia E. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. European Neuropsychopharma 2010; 20: 747–765.

  23. Trautmann-Sponsel RD, Dienel A. Safety of Hypericum extract in mildly to moderately depressed outpatients: a review based on data from three randomized, placebo-controlled trials. J Affective Disorders 2004; 82: 303–307.

  24. Williams E. In RxList. Valium, 2015. Accessed in June 4th at http://www.rxlist.com/valium-sideeffects-drug-center.htm.




2020     |     www.medigraphic.com